Article Trunk



Chemistry / M2 Pharma, “Results of Aprea’s APR-246 with Azacitidine in Mutated Myelodysplastic Syndromes Released.”

06.21.2018 · Posted in Uncategorized
M2 PHARMA-June 21, 2018-Results of Aprea's APR-246 with Azacitidine in Mutated Myelodysplastic Syndromes Released (C)2018 M2 COMMUNICATIONS
  • Boston, Massachusetts- and Stockholm, Sweden-based biopharmaceutical company Aprea Therapeutics has reviewed results at the 2018 European Hematology Association annual meeting from its Phase Ib/II clinical study in mutant myelodysplastic...

Leave a Reply

You must be logged in to post a comment.

%d bloggers like this: